GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » Beneish M-Score
中文

Stereotaxis (Stereotaxis) Beneish M-Score : -4.23 (As of Apr. 24, 2024)


View and export this data going back to 2004. Start your Free Trial

Stereotaxis Beneish M-Score Definition

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.23 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Stereotaxis's Beneish M-Score or its related term are showing as below:

STXS' s Beneish M-Score Range Over the Past 10 Years
Min: -4.24   Med: -3.18   Max: 0.12
Current: -4.23

During the past 13 years, the highest Beneish M-Score of Stereotaxis was 0.12. The lowest was -4.24. And the median was -3.18.


Stereotaxis Beneish M-Score Historical Data

The historical data trend for Stereotaxis's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis Beneish M-Score Chart

Stereotaxis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 -2.97 -1.45 -3.59 -4.23

Stereotaxis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.59 -3.68 -2.78 -3.70 -4.23

Competitive Comparison of Stereotaxis's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Stereotaxis's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stereotaxis Beneish M-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Stereotaxis's Beneish M-Score falls into.



Stereotaxis Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Stereotaxis for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7895+0.528 * 1.1822+0.404 * 0.4766+0.892 * 0.9511+0.115 * 0.664
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0411+4.679 * -0.276886-0.327 * 1.1798
=-4.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $3.82 Mil.
Revenue was 4.565 + 7.799 + 7.859 + 6.548 = $26.77 Mil.
Gross Profit was 2.738 + 4.059 + 4.187 + 3.876 = $14.86 Mil.
Total Current Assets was $33.27 Mil.
Total Assets was $41.91 Mil.
Property, Plant and Equipment(Net PPE) was $8.29 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.60 Mil.
Selling, General, & Admin. Expense(SGA) was $26.43 Mil.
Total Current Liabilities was $13.25 Mil.
Long-Term Debt & Capital Lease Obligation was $5.06 Mil.
Net Income was -5.04 + -5.369 + -4.957 + -5.347 = $-20.71 Mil.
Non Operating Income was 0.003 + 0 + 0.027 + 0 = $0.03 Mil.
Cash Flow from Operations was -2.439 + -0.967 + -2.931 + -2.802 = $-9.14 Mil.
Total Receivables was $5.09 Mil.
Revenue was 7.301 + 7.657 + 6.152 + 7.037 = $28.15 Mil.
Gross Profit was 4.309 + 4.567 + 4.67 + 4.924 = $18.47 Mil.
Total Current Assets was $43.25 Mil.
Total Assets was $53.41 Mil.
Property, Plant and Equipment(Net PPE) was $9.22 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.43 Mil.
Selling, General, & Admin. Expense(SGA) was $26.69 Mil.
Total Current Liabilities was $14.29 Mil.
Long-Term Debt & Capital Lease Obligation was $5.49 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.822 / 26.771) / (5.09 / 28.147)
=0.142766 / 0.180836
=0.7895

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(18.47 / 28.147) / (14.86 / 26.771)
=0.656198 / 0.555078
=1.1822

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (33.267 + 8.286) / 41.909) / (1 - (43.246 + 9.215) / 53.413)
=0.008495 / 0.017823
=0.4766

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=26.771 / 28.147
=0.9511

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.429 / (0.429 + 9.215)) / (0.595 / (0.595 + 8.286))
=0.044484 / 0.066997
=0.664

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(26.426 / 26.771) / (26.688 / 28.147)
=0.987113 / 0.948165
=1.0411

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.062 + 13.247) / 41.909) / ((5.488 + 14.291) / 53.413)
=0.436875 / 0.370303
=1.1798

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-20.713 - 0.03 - -9.139) / 41.909
=-0.276886

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Stereotaxis has a M-score of -4.23 suggests that the company is unlikely to be a manipulator.


Stereotaxis Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Stereotaxis's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Stereotaxis (Stereotaxis) Business Description

Traded in Other Exchanges
Address
710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Executives
Paul J Isaac 10 percent owner 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer director 5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry officer: Chief Legal Officer & Secretar 4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin director 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat director 2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani director 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite officer: VP Research & Development C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730